A shifting landscape: What will be next FDG in PET oncology?

被引：7

作者：

Inoue, T

Oriuchi, N

Tomiyoshi, K

Endo, K

机构：

[1] Yokohama City Univ, Sch Med, Dept Radiol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan

[2] Gunma Univ, Sch Med, Dept Nucl Med, Maebashi, Gumma, Japan

[3] Nishidai Clin Diagnost Imaging Ctr, Radiopharmaceut Div, Tokyo, Japan

来源：

ANNALS OF NUCLEAR MEDICINE | 2002年 / 16卷 / 01期

关键词：

FDG; PET; PET oncology;

D O I：

10.1007/BF02995285

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The tumor-seeking agent most widely used in positron emission tomography (PET) is 2-F-18-fluorodeoxy-D-glucose (FDG). The clinical usefulness of FDG PET has already been proved in detecting, staging and restaging various kinds of malignant tumors, but nuclear medicine physicians suffer from a "diagnostic dilemma," in which a relatively high false positive ratio of FDG PET in diagnosing malignant tumors prevails. To increase more specific tumor uptake or more specific tumor characterization, numerous PET radiopharmaceuticals have been developed, and some of them are being tested in clinical trials. This review will briefly survey the tumor uptake mechanism and clinical significance of representative non-FDG PET radiopharmaceuticals used in clinical trials for patients with cancers.

引用

页码：1 / 9

页数：9

共 85 条

[1] Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings [J].